<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">milmed</journal-id><journal-title-group><journal-title xml:lang="ru">Военная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Military Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-5044</issn><publisher><publisher-name>Белорусский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">milmed-719</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ НАУЧНЫЕ ПУБЛИКАЦИИ. Новые технологии в медицине</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL SCIENTIFIC PUBLICATIONS. New technologies in medicine</subject></subj-group></article-categories><title-group><article-title>Галектин-3 – маркер аневризматической трансформации при дак-ассоциированной аортопатии</article-title><trans-title-group xml:lang="en"><trans-title>Galectin-3 is a marker of aneurysmal transformation in bav-associated aortopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рудой</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Rudoy</surname><given-names>А. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bova</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валюженич</surname><given-names>Я. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Valiuzhenich</surname><given-names>Y. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Урываев</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Uryvaev</surname><given-names>A. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Военно-медицинский факультет в УО «Белорусский государственный медицинский университет»</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2026</year></pub-date><volume>0</volume><issue>3</issue><fpage>95</fpage><lpage>100</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рудой А.С., Бова А.А., Валюженич Я.И., Урываев А.М., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Рудой А.С., Бова А.А., Валюженич Я.И., Урываев А.М.</copyright-holder><copyright-holder xml:lang="en">Rudoy А.S., Bova A.A., Valiuzhenich Y.I., Uryvaev A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://milmed.ejournal.by/jour/article/view/719">https://milmed.ejournal.by/jour/article/view/719</self-uri><abstract><p>Двустворчатый аортальный клапан (ДАК) – один из самых распространенных и гетерогенных врожденных пороков сердца, затрагивающий примерно 0,5–2% популяции населения, часто проявляющийся ассоциированной аортопатией.Научный интерес представляет поиск новых биомаркеров, отражающих патофизиологический процесс в сосудистой стенке и имеющих предсказательную роль для прогноза дилатации и профилактики жизнеугрожающих осложнений. Целью исследования явилось уточнение предикторной роли галектина-3 в качестве потенциального биомаркера аневризматической трансформации ДАК-ассоциированной аортопатии. Обследовано 47 пациентов (22 пациента с ДАК, средний возраст 44 года; 25 здоровых добровольцев, средний возраст 44 года). Измерение сывороточного уровня галектина-3 проводилось с помощью иммуноферментного анализа (Galectin 3 ELISA Kit).Установлено, что повышенный уровень галектина-3 в сыворотке крови у пациентов с ДАК-ассоциированной аортопатией может служить серологическим маркером неблагоприятного прогноза в виде нарушения адаптационных свойств стенки аорты с увеличением размеров диаметра аорты.</p></abstract><trans-abstract xml:lang="en"><p>Bicuspid aortic valve (BAV) is one of the most common and heterogeneous congenital heart diseases, affecting approximately 0.5–2% of the population, often manifested by associated aortopathy. Of scientific interest is the search for new biomarkers reflecting the pathophysiological process in the vascular wall as a prediction of its dilatation in order to prevent a life-threatening condition.The aim of the study was to clarify the predictive role of galectin-3 as a potential biomarker of the aneurysmal transformation of BAV-associated aortopathy.47 patients were examined (22 patients with BAV, mean age 44 years; 25 volunteers, mean age 44 years). The measurement of the serum level of galectin-3 was carried out using an ELISA kit (Galectin 3 ELISA Kit). It has been established that an increased serum level of galectin-3 in patients with BAV-associated aortopathy may serve as a serological marker indicating a poor prognosis, accompanied by an increase in the size of the aorta diameter.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>бикуспидальный аортальный клапан</kwd><kwd>ДАК-ассоциированная аортопатия</kwd><kwd>галектин-3</kwd><kwd>аневризма аорты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bicuspid aortic valve</kwd><kwd>BAV-associated aortopathy</kwd><kwd>galectin-3</kwd><kwd>aortic aneurysm</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Argüeso, P., &amp; Panjwani, N.. Focus on Molecules: Galectin-3. Experimental Eye Research, 2011, 92(1), 2–3.</mixed-citation><mixed-citation xml:lang="en">Argüeso, P., &amp; Panjwani, N.. Focus on Molecules: Galectin-3. Experimental Eye Research, 2011, 92(1), 2–3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Borger M. A. et al. The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve–related aortopathy: Full online-only version // The Journal of thoracic and cardiovascular surgery. – 2018. – Т. 156. – № 2. – С. e41–e74.</mixed-citation><mixed-citation xml:lang="en">Borger M. A. et al. The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve–related aortopathy: Full online-only version // The Journal of thoracic and cardiovascular surgery. – 2018. – Т. 156. – № 2. – С. e41–e74.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol. 2015;182:168–170.</mixed-citation><mixed-citation xml:lang="en">Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol. 2015;182:168–170.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.</mixed-citation><mixed-citation xml:lang="en">Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fort-Gallifa I. et al. Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation //In ternational journal of molecular sciences. – 2017. – Т. 18. – № 5. – С. 973.</mixed-citation><mixed-citation xml:lang="en">Fort-Gallifa I. et al. Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation //In ternational journal of molecular sciences. – 2017. – Т. 18. – № 5. – С. 973.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Hørslev-Petersen K, Junker P. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015;82:70–75.</mixed-citation><mixed-citation xml:lang="en">Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Hørslev-Petersen K, Junker P. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015;82:70–75.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Sur­gery. J Vasc Surg. 1991;13:452-8.</mixed-citation><mixed-citation xml:lang="en">Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Sur­gery. J Vasc Surg. 1991;13:452-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmer­mans J. A clinical appraisal of different Z-score equations for aortic root assessment in the diagnostic evaluation of Marfan syndrome. Genet Med. 2013;15:528–532.</mixed-citation><mixed-citation xml:lang="en">Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmer­mans J. A clinical appraisal of different Z-score equations for aortic root assessment in the diagnostic evaluation of Marfan syndrome. Genet Med. 2013;15:528–532.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kinoshita N, Mimura J, Obayashi C, Katsukawa F, Onishi S, Yamazaki H. Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J. 2000;139:723–728.</mixed-citation><mixed-citation xml:lang="en">Kinoshita N, Mimura J, Obayashi C, Katsukawa F, Onishi S, Yamazaki H. Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J. 2000;139:723–728.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Medvedeva EA, Berezin II, Surkova EA, Yaranov DM, Shchukin YV. Galectin-3 in patients with chronic heart failure: Association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016;64:595–602.</mixed-citation><mixed-citation xml:lang="en">Medvedeva EA, Berezin II, Surkova EA, Yaranov DM, Shchukin YV. Galectin-3 in patients with chronic heart failure: Association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016;64:595–602.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, Donato LJ, Saenger AK. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48:1337–1340.</mixed-citation><mixed-citation xml:lang="en">Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, Donato LJ, Saenger AK. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48:1337–1340.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh, S. F. Recommendations for the evaluation of leftvent­ricular diastolic function by echocardiography / S. F. Nagueh [et al.] // Journal of the American society of echocardiography. – 2009. – Vol. 22. – P. 108–133.</mixed-citation><mixed-citation xml:lang="en">Nagueh, S. F. Recommendations for the evaluation of leftvent­ricular diastolic function by echocardiography / S. F. Nagueh [et al.] // Journal of the American society of echocardiography. – 2009. – Vol. 22. – P. 108–133.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123–128.</mixed-citation><mixed-citation xml:lang="en">Newlaczyl AU, Yu LG. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123–128.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nistri, S., Sorbo, M. D., Marin, M. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart, 1999, 82(1), 19–22.</mixed-citation><mixed-citation xml:lang="en">Nistri, S., Sorbo, M. D., Marin, M. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart, 1999, 82(1), 19–22.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood) 2015;240:1019–1028.</mixed-citation><mixed-citation xml:lang="en">Oliveira FL, Gatto M, Bassi N, Luisetto R, Ghirardello A, Punzi L, Doria A. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood) 2015;240:1019–1028.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Papaspyridonos M., McNeill E., de Bono J. P., Smith A., Burnand K. G., Channon K. M., Greaves D. R. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler. Thromb. Vasc. Biol. 2008;28:433–440.</mixed-citation><mixed-citation xml:lang="en">Papaspyridonos M., McNeill E., de Bono J. P., Smith A., Burnand K. G., Channon K. M., Greaves D. R. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler. Thromb. Vasc. Biol. 2008;28:433–440.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mahadevia, R., Barker, A. J., Schnell, S., Entezari, P. Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation, 2014, 129(6), 673–682.</mixed-citation><mixed-citation xml:lang="en">Mahadevia, R., Barker, A. J., Schnell, S., Entezari, P. Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation, 2014, 129(6), 673–682.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014;52:1413–1423.</mixed-citation><mixed-citation xml:lang="en">Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014;52:1413–1423.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2017;16:34–47.</mixed-citation><mixed-citation xml:lang="en">Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2017;16:34–47.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with Stable heart failure and healthy adults. Clin Chem. 2016;62:360–366.</mixed-citation><mixed-citation xml:lang="en">Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with Stable heart failure and healthy adults. Clin Chem. 2016;62:360–366.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Stone J. R. et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases //Cardiovascular Pathology. – 2015. – Т. 24. – № 5. – С. 267–278.</mixed-citation><mixed-citation xml:lang="en">Stone J. R. et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases //Cardiovascular Pathology. – 2015. – Т. 24. – № 5. – С. 267–278.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ward, C. Clinical significance of the bicuspid aortic valve. Heart, 2000, 83(1), 81–85.</mixed-citation><mixed-citation xml:lang="en">Ward, C. Clinical significance of the bicuspid aortic valve. Heart, 2000, 83(1), 81–85.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wolak A. et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area // JACC: Cardiovascular Imaging. – 2008. – Т. 1. – № 2. – С. 200–209.</mixed-citation><mixed-citation xml:lang="en">Wolak A. et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area // JACC: Cardiovascular Imaging. – 2008. – Т. 1. – № 2. – С. 200–209.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
